INTRO SPEECH
Serious infections, particularly in vulnerable patients, represent a global healthemergency, especially when caused by multidrug-resistant microorganisms.
Among Gram-negative bacteria, carbapenem-resistant Enterobacterales,Pseudomonas aeruginosa, and Acinetobacter baumannii, primarily due to theproduction of ß-lactamases, are on the rise and pose a significant challenge forphysicians worldwide.
Although Gram-positive infections receive comparatively less attention,Staphylococcus spp. and Enterococcus spp. infections are associated withhigh morbidity and mortality, particularly in cases of bloodstream infections,endocarditis, or implant-associated infections. Therefore, it is crucial to evaluatethe latest advancements in therapeutic options.
Sepsis caused by these pathogens presents significant immunological complexities, and its diagnosis using biomarkers remains challenging. However,precise diagnosis, timely antimicrobial therapy, and appropriate considerationof antimicrobial pharmacokinetics across different patient populations areessential to improving patient outcomes. In this context, the implementation ofrapid molecular tests for the detection of sepsis biomarkers, the identification ofetiological microorganisms, and the determination of resistance mechanisms is imperative for altering the course of the disease.
Furthermore, immunocompromised patients, such as those with neutropenia,are at increased risk of fungal infections and SARS-CoV-2 infection. Accordingly,this course will highlight emerging antifungal agents currently in development and discuss protocols for managing COVID-19 in immunosuppressed patients.
Lastly, we will address contemporary challenges in HIV care and their impact onpatients’ quality of life.
Carlo Tascini
Alex Soriano Viladomin